Physician profile
Behnam Ebrahimi
NPI 1033165139
$208,208.35
in general payments reported to CMS, 2019-2025
45 companies · $17K in 2025
The $17K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114K · 2020: $20K · 2021: $13K · 2022: $22K · 2023: $10K · 2024: $12K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $4,460 · Food and Beverage: $3,046 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,815.00 |
| Consulting Fee | $4,460.00 |
| Food and Beverage | $3,046.48 |
| Education | $399.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $93,526.35 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Genentech USA, INC. | $48,836.11 | 2019-2022 | |
| Celgene Corporation | $24,399.76 | 2019-2025 | Reblozyl, Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $10,986.28 | 2019 | |
| Merck Sharp & Dohme LLC | $10,010.95 | 2019-2024 | Keytruda, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $4,316.83 | 2019-2025 | |
| Janssen Biotech, INC. | $4,176.11 | 2019-2025 | Talvey, Darzalex, Erleada |
| Pfizer INC. | $3,152.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,563.08 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Novartis Pharmaceuticals Corporation | $1,516.01 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,341.40 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Astellas Pharma US INC | $955.84 | 2020-2025 | Padcev, Vyloy |
| Lilly USA, LLC | $667.26 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Novocure Gmbh | $200.00 | 2022 | |
| Seagen INC. | $153.25 | 2022-2023 | Tukysa |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behnam Ebrahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.